Varicellazostervaccine

Generic name
Varicellazostervaccine
Brand name
ATC Code
J07BK01
Compare …

Varicellazostervaccine

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information is present at this moment.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Active immunization against varicella zoster
  • Intramuscular
    • 9 months up to 12 months
      [1]

      • 2 doses (at least 1350 pfu/dose) with an interval of at least 3 months.

    • 12 months up to 13 years
      [1]

      • 2 doses (at least 1350 pfu/dose) with an interval of at least 1 month

      • Children with an asymptomatic HIV infection (CDC class 1) and an age-specific CD4+ T-lymphocyte percentage > 25% must be given two doses, with an interval of 12 weeks.

    • ≥ 13 years
      [1]

      • 2 doses (at least 1350 pfu/dose) with an interval of at least 1-2 months

  • Subcutaneous
    • 9 months up to 12 months
      [1]

      • 2 doses (at least 1350 pfu/dose) with an interval of at least 3 months

    • 12 months up to 13 years
      [1]

      • 2 doses (at least 1350 pfu/dose) with an interval of at least 1 month

      • Children with an asymptomatic HIV infection (CDC class 1) and an age-specific CD4+ T-lymphocyte percentage > 25% must be given two doses, with an interval of 12 weeks.

    • ≥ 13 years
      [1]

      • 2 doses (at least 1350 pfu/dose) with an interval of at least 1-2 months

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Live attenuated vaccines (e.g., varicella zoster vaccine) should not be given to infants exposed to infliximab in utero until 12 months after birth. Administration of a live attenuated vaccine to a breastfed infant while the mother is receiving infliximab is not recommended unless serum levels of infliximab are undetectable in the infant. These infants may be at increased risk of infection, including severe disseminated infection that can become fatal. [DHPC]

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

VIRAL VACCINES

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Encephalitis vaccines
J07BA02
J07BA01
Influenza vaccines
J07BB02
Hepatitis vaccines
J07BC20
J07BC02
J07BC01
Measles vaccines
J07BD52
Poliomyelitis vaccines
J07BF03
Rabies vaccines
J07BG01
Rota virus diarrhea vaccines
J07BH01
Yellow fever vaccines
J07BL01
Papillomavirus vaccines
J07BM03
J07BM02
Other viral vaccines
J07BX04

References

  1. Merck Sharp & Dohme BV, SmPC Provarivax (RVG 29215) 24-02-2017, www.geneesmiddeleninformatiebank.nl
  2. Representatives of marketing authorisation holders of infliximab, DHPC Infliximab 07 maart 2022,, https://www.cbg-meb.nl/documenten/brieven/2022/03/08/dhpc-infliximab

Changes

Therapeutic Drug Monitoring


Overdose